Has tucatinib been included in the reimbursement scope of national medical insurance?

Tucatinib (Tucatinib), as a new type of HER2 targeted small molecule tyrosine kinase inhibitor, is mainly used to treat patients with HER2 positive advanced breast cancer. Although it has received widespread attention and recognition in the field of international cancer treatment, the original drug of tucatinib has not yet been officially marketed in mainland China, and therefore has not yet been included in the scope of national medical insurance reimbursement. This means that domestic patients are temporarily unable to obtain the drug through medical insurance channels.

Since tucatinib is not yet commercially available in China and is not included in the medical insurance catalog, patients need to rely on other ways to obtain treatment drugs. In contrast, the original drug tucatinib is already circulating in markets in Europe and other regions. Its specifications are usually 150mg*84 tablets and the price is relatively high. Each box may be sold for more than 40,000 yuan, which imposes a heavy financial burden.

It is worth noting that generic versions of tucatinib have appeared in overseas markets. For example, the price of a generic drug produced by a Lao pharmaceutical factory in the format of 150mg*60 tablets is about more than 2,000 yuan, which is much lower than the original drug. These generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, providing a more affordable option for patients who cannot afford the high-priced original drugs.

Generally speaking, tucatinib has not yet entered China’s medical insurance system, and domestic patients still face certain difficulties and economic pressure in obtaining the drug. With the future launch of domestic or imported drugs and the update of medical insurance policies, the accessibility of tucatinib is expected to increase, bringing good news to more patients with HER2 positive advanced breast cancer.

Reference materials:https://www.drugs.com/